PLANTATION, Fla., March 27 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) and its majority-owned subsidiary, Viragen International, Inc.
(OTC Bulletin Board: VGNI), today announced that Acta Oncologica, a leading
journal in clinical oncology, has accepted to publish an article profiling
Multiferon(R) (multi-subtype, natural human alpha interferon) in the adjuvant
treatment of high-risk (Stages IIb-III) malignant melanoma.
The article will report on the use of Multiferon(R) following dacarbazine
(DTIC) in a clinical trial that demonstrated a statistically significant
advantage over untreated controls in terms of distant-metastases-free survival
and overall survival. It is expected to be published this summer.
About Acta Oncologica:
Published eight times per year, Acta Oncologica is one of the leading
journals in clinical oncology and related disciplines, and accepts articles
within all fields of clinical cancer research from applied basic research to
cancer nursing and psychological aspects of cancer. It is the official
journal of the five Nordic oncological societies, and the members of the
editorial committee represent these societies.
About Viragen, Inc.:
With global operations in the U.S., Scotland and Sweden, Viragen is a
biotechnology company engaged in the research, development, manufacture and
commercialization of pharmaceutical proteins for the treatment of viral
diseases and cancers. Our product portfolio includes: Multiferon(R) (multi-
subtype, natural human alpha interferon) targeting a broad range of infectious
and malignant diseases; and humanized monoclonal antibodies targeting specific
antigens over-expressed on many types of cancers. We are also pioneering the
development of Avian Transgenic Technology, with the renowned Roslin
Institute, as a revolutionary manufacturing platform for the large-scale,
efficient and economical production of human therapeutic proteins and
antibodies.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "believes," "expects,"
"potential," "plans," "suggests," "may," "should," "could," "intends," or
similar expressions. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. In particular, management's
expectations regarding future research, development and/or commercial results
could be affected by, among other things, uncertainties relating to clinical
trials and product development; availability of future financing; unexpected
regulatory delays or government regulation generally; the Company's ability to
obtain or maintain patent and other proprietary intellectual property
protection; and competition in general. Forward-looking statements speak only
as to the date they are made. The Company does not undertake to update
forward-looking statements to reflect circumstances or events that occur after
the date the forward-looking statements are made. Acta Oncologica reserves
the right to change the timing and/or content for planned future publications.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
